Inflammation and cardiovascular complications in chronic kidney disease

References

• Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32: S112–9
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology 2006; 11: 36–41
   PubMed Web of Science ®Google Scholar
• Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002; 106: 100–10
   PubMed Web of Science ®Google Scholar
• McDonald SP, Craig JC. Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med 2004; 350: 2654–62
   PubMed Web of Science ®Google Scholar
• Mitsnefes MM. Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol 2008; 23: 27–39
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–305
   PubMed Web of Science ®Google Scholar
• Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347–54
   PubMed Web of Science ®Google Scholar
• Parfrey PS, Foley RN, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease. Kidney Int 1995; 47: 186–92
   PubMedGoogle Scholar
• Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, et al. Effect of hemoglobin levels in hemodialysis patients with symptomatic cardiomyopathy. Kidney Int 2002; 58: 1325–35
   Google Scholar
• London GM, De Vernejoul MC, Fabiani F, Marchais SJ, Guerin AP, Metivier F, et al. Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int 1987; 32: 900–7
   PubMed Web of Science ®Google Scholar
• Mitsnefes MM, Daniels SR, Schwartz SA, Khoury P, Meyer RA, Strife CF. Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol 2000; 14: 892–8
   Google Scholar
• Stack AG, Bloembergen WE. Study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001; 38: 992–1000
   PubMed Web of Science ®Google Scholar
• Mitsnefes MM, Kimball TR, Witt SA, Glascock BJ, Khoury PR, Daniels SR. Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation 2003; 107: 864–8
   PubMed Web of Science ®Google Scholar
• Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM. Carotid arterial thickness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998; 32: 570–4
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 2953–61
   Google Scholar
• Nayir A, Bilge I, Kilicaslan I, Ander H, Mere S, Siren A. Arterial changes in pediatric haemodialysis patients undergoing renal transplantation. Nephrol Dial Transplant 2001; 6: 2041–7
   Google Scholar
• Shilipak MG, Fried LF, Cushman M. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293: 1737–45
   Google Scholar
• Muntner PHJ, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005; 16: 529–38
   PubMed Web of Science ®Google Scholar
• Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO4, CaxPO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis. J Am Soc Nephrol 2001; 12: 2131–8
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004; 24: 469–73
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol 2004; 15: S77–80
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–26
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 2006; 11: 36–41
   PubMed Web of Science ®Google Scholar
• Jofre R, Rodriquez-Benitez P, Lopez-Gomez JM, Perez-Garcia R. Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol 2006; 17: S274–80
   PubMedGoogle Scholar
• Stenvenkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoitis-Filho R, Riella M, et al. IL-10, IL-6, and TNF-α: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney Int 2005; 67: 1216–33
   Google Scholar
• Stenvinkel P, Heimburger O, Paultre F. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899–911
   PubMed Web of Science ®Google Scholar
• Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanneh C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648–58
   PubMed Web of Science ®Google Scholar
• Dulcloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin J-M. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002; 62: 1417–22
   Google Scholar
• Menon V, Greene T, Wang X. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766–72
   PubMed Web of Science ®Google Scholar
• Park CW, Shin YS, Kim CM. Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis 2002; 40: 1230–9
   PubMed Web of Science ®Google Scholar
• Pascer V, Willerson J, Yeh E. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165–8
   Google Scholar
• Zwaka T, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194–7
   PubMed Web of Science ®Google Scholar
• Verma S, Kuliszewski M, Li S, Szmitko P, Zucco L, Wang C, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109: 2058–67
   PubMed Web of Science ®Google Scholar
• Yeh ETH. CRP as a mediator of disease. Circulation 2004;109(Suppl II)11–14.
   Google Scholar
• Paul A, Kerry WS, Li L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109: 647–55
   PubMed Web of Science ®Google Scholar
• Hirshfield GM, Gallimore JR, Kahan MC, Hutchinson WL, Sabin CA, Benson GM, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 2005; 102: 8309–11
   Google Scholar
• Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1154–60
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation. Circulation 2006; 113: e152–5
   PubMedGoogle Scholar
• Ece A, Gurkan F, Kervancioglu M, Kocamaz H, Gunes A, Atamer Y, et al. Oxidative stress, inflammation and early cardiovascular damage in children with chronic renal failure. Pediatr Nephrol 2006; 21: 545–52
   PubMed Web of Science ®Google Scholar
• Garibotto G, Sofia A, Procopio V, Villaggio B, Tarroni A, Di Martino M, et al. Peripheral tissue release of interleukin-6 in patients with chronic kidney diseases: effects of end-stage renal disease and microinflammatory state. Kidney Int 2006; 70: 384–90
   Google Scholar
• Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid atherosclerosis in dialysis patients: association to Chlamydia pneumoniae seropositivity. Am J Kidney Dis 2002; 39: 274–82
   PubMed Web of Science ®Google Scholar
• Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients. J Am Soc Nephrol 2006; 17: S169–73
   Google Scholar
• Tzoulaki I, Murray GD, Lee AJ, Rumpley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005; 112: 976–83
   PubMed Web of Science ®Google Scholar
• Nakanishi I, Moutabarrik A, Okada N, Kitamura E, Hayashi A, Syouji T, et al. Interleukin-8 in chronic renal failure and dialysis patients. Nephrol Dial Transplant 1994; 9: 1435–42
   PubMed Web of Science ®Google Scholar
• Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998; 54: 236–44
   PubMed Web of Science ®Google Scholar
• Ryden M, Arner P. Tumour necrosis factor-α in human adipose tissue—from signaling mechanisms to clinical implications. J Intern Med 2007; 262: 431–8
   Google Scholar
• Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167–75
   PubMed Web of Science ®Google Scholar
• Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with ESRD. J Am Soc Nephrol 2002; 13: 1894–900
   PubMed Web of Science ®Google Scholar
• Lai HL, Kartal J, Mitsnefes MM. Hyperinsulinemia in pediatric patients with chronic kidney disease: the role of tumor necrosis factor-α. Pediatr Nephrol 2007; 22: 1751–6
   Google Scholar
• Mak RH. Insulin and its role in chronic kidney disease. Pediatr Nephrol 2008; 23: 355–62
   Google Scholar
• Garcia de Vinuesa S, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, et al. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 2006; 17: S206–12
   Google Scholar
• Chen NX, Duan D, O'Neill KD, Moe SM. High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. Nephrol Dial Transplant 2006; 21: 3435–42
   PubMed Web of Science ®Google Scholar
• Olese P, Nguyen K, Wogensen L, Ledet T, Rasmussen LM. Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high dose insulin. Am J Physiol Heart Circ Physiol 2007; 292: H1058–64
   Google Scholar
• Saland JM, Ginsberg HN. Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol 2007; 22: 1095–112
   Google Scholar
• Mak RH, Cheung W, Cone RD, Marks DL. Leptin and inflammation-associated cachexia in chronic kidney disease. Kidney Int 2006; 69: 794–7
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473–6
   PubMed Web of Science ®Google Scholar
• Shamsuzzaman AS, Winnicki M, Wolk R, Svatikova A, Phillips BG, Davison DE, et al. Independent association between plasma leptin and CRP in healthy humans. Circulation 2004; 109: 2181–5
   PubMed Web of Science ®Google Scholar
• Ble A, Windham G, Bandinelli S, Taub DD, Volpato S, Bartali B, et al. Relation of plasma leptin to C-reactive protein in older adults (from the Invecchiare nel Chianti study). Am J Cardiol 2005; 96: 991–5
   Google Scholar
• Sharma K, Considive RV, Michael B, Dunn SR, Weisberg LS, Kurnik BR, et al. Plasma leptin is partly cleared from the circulation by the kidney. Kidney Int 1997; 51: 1980–5
   PubMed Web of Science ®Google Scholar
• Wang Y, Kuropetwinski KK, White DW, Hawley TS, Hawley RG, Tartaglia LA, et al. Leptin receptor action in hepatic cells. J Biol Chem 1997; 272: 16216–23
   PubMed Web of Science ®Google Scholar
• Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595–9
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79–83
   Google Scholar
• Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134–41
   PubMed Web of Science ®Google Scholar
• Mitsnefes M, Kartal J, Khoury P, Daniels S. Adiponectin in children with chronic kidney disease: role of adiposity and kidney dysfunction. Clin J Am Soc Nephrol 2007; 2: 46–50
   Google Scholar
• Long DA, Price KL, Herrera-Acosta J, Johnson RJ. How does angiotensin II cause renal injury?. Hypertension 2004; 43: 722–3
   Google Scholar
• Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. Circ Res 2007; 101: 441–54
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega M, Bustos C, Hernandez-Prese MA, Lorenzo O, Plaza JJ, Equido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa β activation and monocyte-chemoattractant protein 1 synthesis. J Immunol 1998; 161: 430–9
   PubMed Web of Science ®Google Scholar
• Pawlak K, Pawlak D, Mysliwiec M. Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular disease. Am J Nephrol 2004; 24: 635–40
   Web of Science ®Google Scholar
• Pawlak K, Pawlak D, Mysliwiec M. Inflammation but not oxidative stress is associated with beta-chemokine levels and prevalence of cardiovascular disease in uraemic patients. Cytokine 2006; 35: 258–62
   Google Scholar
• Yu C, Gong R, Rifai A, Tolbert EM, Dworkin LD. Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. J Am Soc Nephrol 2007; 18: 750–9
   PubMedGoogle Scholar
• Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756–67
   PubMed Web of Science ®Google Scholar
• Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 2007; 18: 1093–102
   PubMed Web of Science ®Google Scholar
• Ranjbaran H, Sokol SI, Gallo A, Eid RE, Iakimov AO, D'Alessio A, et al. An inflammatory pathway of IFN-gamma production in coronary atherosclerosis. J Immunol 2007; 178: 592–604
   PubMedGoogle Scholar
• Bobryshev YV, Lord RS. Co-accumulation of dendritic cells and natural killer T cells within rupture-prone regions in human atherosclerotic plaques. J Histochem Cytochem 2005; 53: 781–5
   PubMed Web of Science ®Google Scholar
• Lo JC, Chertow GM, Go AS, Hsu C-Y. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int 2005; 67: 1047–52
   PubMed Web of Science ®Google Scholar
• Zoccali C, Tripepi G, Cutrupi S, Pizzini P, Mallamaci F. Low triiodothyronine: a new facet of inflammation in end-stage renal disease. J Am Soc Nephrol 2005; 16: 2789–95
   PubMed Web of Science ®Google Scholar
• Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, et al. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 2003; 107: 708–13
   PubMed Web of Science ®Google Scholar
• Malik FS, Mehra MR, Uber PA, Park MH, Scott RL, Van Meter CH. Intravenous thyroid hormone supplementation in heart failure with cardiogenic shock. J Card Fail 1999; 5: 31–7
   Google Scholar
• Bettendorf M, Schmidt KG, Grulick-Henn J, Ulmer HE, Heinrich UE. Tri-iodothyronine treatment in children after cardiac surgery: a double-blind, randomized placebo study. Lancet 2000; 356: 529–34
   PubMed Web of Science ®Google Scholar
• Enia G, Panuccio V, Cutrupi S, Pizzini P, Tripepi G, Mallamaci F, et al. Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2007; 22: 538–44
   PubMedGoogle Scholar
• Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis 2005; 46: 489–500
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kuwae N, Wu DY, Shantouf RS, Fouque D, Anker SD, et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 2006; 83: 202–10
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793–808
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, McAllister CJ, Alcorn H, Jr, Kopple JD, et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant 2005; 20: 1880–9
   PubMed Web of Science ®Google Scholar
• Shinaberger CS, Kilpatrick RD, Regidor DL, McAllister CJ, Greenland S, Kopple JD, et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients. Am J Kidney Dis 2006; 48: 37–49
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Block G, Acallister CJ, Humphreys MH, Kopple JD. Appetite and inflammation, nutrition anemia and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299–307
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Balakrishnan VS. The kidney disease wasting: inflammation, oxidative stress, and diet-gene interaction. Hemodialysis Int 2006; 10: 315–25
   PubMedGoogle Scholar
• Simmons EM, Langone A, Sezer MT, Vella JP, Recupero P, Morrow JD, et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 2005; 79: 914–9
   PubMed Web of Science ®Google Scholar
• Cueto-Manzano AM, Morales-Buenrostro LE, Gonzalez-Espinoza L, Gonzalez-Tableros N, Martin-del-Campo F, Correa-Rotter R, et al. Markers of inflammation before and after renal transplantation. Transplantation 2005; 80: 47–51
   Google Scholar
• Petersen AMW, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005; 98: 1154–62
   PubMed Web of Science ®Google Scholar
• Johansen KL. Exercise in the end-stage renal disease population. J Am Soc Nephrol 2007; 18: 1845–54
   PubMed Web of Science ®Google Scholar
• Castaneda C, Gordon PL, Parker RC, Uhlin KL, Roubenoff R, Levey AS. Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 2004; 43: 607–16
   PubMed Web of Science ®Google Scholar
• Zaluska A, Zaluska WT, Bednarek-Skublewska A, Ksiazek A. Nutrition and hydration status improve with exercise training using stationary cycling during hemodialysis (HD) in patients with end-stage renal disease (ESRD). Ann Univ Curie Sklodowska 2002; 57: 342–6
   PubMedGoogle Scholar
• Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? what do we need to learn? where do we go from here?. Am J Kidney Dis 1998; 32: 853–906
   PubMed Web of Science ®Google Scholar
• Goldstein SL, Leung JC, Silverstein DM. Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. Clin J Am Soc Nephrol 2007; 1: 979–86
   Google Scholar
• Palinski W, Sotirios T. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002; 13: 1673–81
   PubMed Web of Science ®Google Scholar
• Strippoli GFM, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials. BMJ 2008; 336: 645–51
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621–7
   PubMed Web of Science ®Google Scholar
• Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96: 1398–402
   PubMed Web of Science ®Google Scholar